首页> 中文期刊> 《骨研究:英文》 >The association between the baseline bone resorption marker CTX and incident dysglycemia after 4 years

The association between the baseline bone resorption marker CTX and incident dysglycemia after 4 years

         

摘要

Bone is an endocrine organ involved in modulating glucose homeostasis. The role of the bone formation marker osteocalcin(OCN) in predicting diabetes was reported, but with conflicting results. No study has explored the association between baseline bone resorption activity and incident diabetes or prediabetes during follow-up. Our objective was to examine the relationship between the baseline bone resorption marker crosslinked C-telopeptide of type I collagen(CTX) and glycemic dysregulation after 4 years. This longitudinal study was conducted in a university teaching hospital. A total of 195 normal glucose tolerant(NGT) women at baseline were invited for follow-up. The incidence of diabetes and prediabetes(collectively defined as dysglycemia) was recorded. A total of 128 individuals completed the 4-year study. The overall conversion rate from NGT to dysglycemia was 31.3%. The incidence of dysglycemia was lowest in the middle tertile [16.3%(95% confidence interval(CI), 6.8%–30.7%)] compared with the lower [31.0%(95%CI, 17.2%–46.1%)] and upper [46.5%(95% CI, 31.2%–62.6%)] tertiles of CTX, with a significant difference seen between the middle and upper tertiles(P = 0.002 5). After adjusting for multiple confounding variables, the upper tertile of baseline CTX was associated with an increased risk of incident dysglycemia, with an odds ratio of 7.09(95% CI, 1.73–28.99) when the middle tertile was the reference. Osteoclasts actively regulate glucose homeostasis in a biphasic model that moderately enhanced bone resorption marker CTX at baseline provides protective effects against the deterioration of glucose metabolism, whereas an overactive osteoclastic function contributes to an increased risk of subsequent dysglycemia.

著录项

  • 来源
    《骨研究:英文》 |2017年第003期|P.235-241|共7页
  • 作者单位

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

    Shanghai Institute ofEndocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai, China [2]Department of Geriatrics,Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China [3]Department of Endocrine and Metabolic Diseases,Zhong Shah Hospital, Fudan University, Shanghai, China;

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

    Shanghai Institute ofEndocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai, China [2]Department of Geriatrics,Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China [3]Department of Endocrine and Metabolic Diseases,Zhong Shah Hospital, Fudan University, Shanghai, China;

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

    [1]Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;

  • 原文格式 PDF
  • 正文语种 CHI
  • 中图分类 钙、磷、镁;
  • 关键词

    代谢异常 CTX 骨吸收 血糖 基线 标记 事件 中间水平;

    机译:代谢异常 CTX 骨吸收 血糖 基线 标记 事件 中间水平;
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号